OFATUMUMAB+CHOP PROTOKOLÜ

Kaynaklar:

1-Teeling, J.L. Mackus, W.J.M., Wiegman, L.J.J.M., van den Brakel, J.H.N., Beers, S.A., French, R.R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J.W., Parren, P.W.H.I., Glennie, M.J. & van de Winkel, J.G.J. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol, 177, 362– 371.

2-Tsimberidou, A.M., O'Brien, S.M., Cortes, J.E., Faderl, S., Andreeff, M., Kantarjian, H.M., Keating, M.J. & Giles, F.J. (2002) Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma, 43, 767– 772.

3-Scholar Tsimberidou, A.M., Kantarjian, H.M., Cortes, J., Thomas, D.A., Faderl, S., Garcia-Manero, G., Verstovsek, S., Ferrajoli, A., Wierda, W., Alvarado, Y., O'Brien, S.M., Albitar, M., Keating, M.J. & Giles, F.J. (2003) Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich. Cancer, 97, 1711– 1720.

4-Tsimberidou, A.-M., O'Brien, S., Khouri, I., Giles, F.J., Kantarjian, H.M., Champlin, R., Wen, S., Do, K.-A., Smith, S.C., Lerner, S., Freireich, E.J. & Keating, M.J. (2006) Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol, 24, 2343– 2351.

5-Tsimberidou, A.M., Wierda, W.G., Plunkett, W., Kurzrock, R., O'Brien, S., Wen, S., Ferrajoli, A., Ravandi-Kashani, F., Garcia-Manero, G., Estrov, Z., Kipps, T.J., Brown, J.R., Fiorentino, A., Lerner, S., Kantarjian, H.M. & Keating, M.J. (2008) Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol, 26, 196– 203.

6-Tsimberidou, A.M., Wierda, W.G., Wen, S., Plunkett, W., O'Brien, S., Kipps, T.J., Jones, J.A., Badoux, X., Kantarjian, H. & Keating, M.J. (2013) Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk, 13, 568– 574.

7- Scholar Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, T., Furman, R.R., Hillmen, P., Trneny, M., Dyer, M.J.S., Padmanabhan, S., Piotrowska, M., Kozak, T., Chan, G., Davis, R., Losic, N., Wilms, J., Russell, C.A. & Osterborg, A. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol, 28, 1749– 1755.

8- Toby A Eyre, Ruth Clifford, Adrian Bloor, et al. NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. Br J Haematol . 2016 Oct;175(1):43-54.